Company intelligence / Profile preview

Idis

Burton-On-Trent, Staffordshire, United Kingdom

Ownership: Private
Employees: ~189
Development stage: Other

Overview

Idis was a leading provider of unlicensed pharmaceuticals and Managed Access Programmes (MAPs) for investigational drugs, achieving over 90% market share among top 25 pharma companies by 2015. The company was acquired by Clinigen Group plc in April 2015 and subsequently dissolved on 28 May 2024.

Industry: Drug Discovery Services

Partnerships

Onyx Pharmaceuticals

Beyond the preview

Go deeper on Idis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Idis.